Neurological (Stroke Phase II)

Our clinical focus in the neurological area involves evaluating the efficacy of MultiStem® cell therapy to treat ischemic stroke.  We have completed an exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke. The randomized, double-blind, placebo-controlled trial was conducted at 33 sites in the United States and the United Kingdom.  In April 2015, we announced interim results, and in February 2016, and although the study did not achieve the pre-specified efficacy endpoint, we observed favorable safety and tolerability and promising evidence of efficacy, especially when patients were treated within 36 hours of the occurrence of a stroke.  In February 2016, we announced promising one-year results from this Phase 2 study, which showed statistically significant clinical improvement when evaluating all subjects, as evidenced by the proportion of patients treated with MultiStem that achieved an “Excellent Outcome”.  This measure reflects complete or essentially complete recovery in each of three well-established clinical rating ...
More